Get Real Time Here
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Stock (NASDAQ:PTGX), Quotes and News Summary
Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.
| Open17.600 | Close17.130 |
| Vol / Avg.573.195K / 884.078K | Mkt Cap985.493M |
| Day Range17.030 - 17.600 | 52 Wk Range7.240 - 30.100 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | -0.680 | -0.0300 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-25 | JP Morgan | Brian Cheng | Maintains | OverweightOverweight | Lowers | 36.00 | 34.00 |
| 2023-08-04 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-10 | HC Wainwright & Co. | Douglas Tsao | Reiterates | BuyBuy | Maintains | - | 38.00 |
| 2023-07-06 | JMP Securities | Jonathan Wolleben | Maintains | Market OutperformMarket Outperform | Raises | 28.00 | 35.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | -2.5% | 985.5M |
| ETNB | 89bio | 2.32% | 1.2B |
| COGT | Cogent Biosciences | -0.1% | 837.6M |
| SNDX | Syndax Pharmaceuticals | 3.3% | 1.1B |
| REPL | Replimune Group | -0.6% | 973.4M |
How do I buy Protagonist Therapeutics (PTGX) stock?
You can purchase shares of Protagonist Therapeutics (NASDAQ: PTGX) through any online brokerage.
Who are Protagonist Therapeutics's (PTGX) competitors?
Other companies in Protagonist Therapeutics’s space includes: 89bio (NASDAQ:ETNB), Cogent Biosciences (NASDAQ:COGT), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ: PTGX) was reported by JP Morgan on Monday, September 25, 2023. The analyst firm set a price target for 34.00 expecting PTGX to rise to within 12 months (a possible 98.48% upside). 12 analyst firms have reported ratings in the last year.
Current Stock Price for Protagonist Therapeutics (PTGX)?
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $17.13 last updated Today at September 28, 2023 at 8:00 PM UTC.
Does Protagonist Therapeutics (PTGX) pay a dividend?
There is no dividend information for Protagonist Therapeutics.
When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?
Protagonist Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is Protagonist Therapeutics (PTGX) going to split?
There is no upcoming split for Protagonist Therapeutics.
What sector and industry does Protagonist Therapeutics (PTGX) operate in?
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.